The variant occurs in a gene involved with inflammation and immune response. The findings add to growing evidence linking inflammation and immune response with the development of lung cancer, according to the study authors.
They looked at more than 1,400 variants in inflammation- and immunity-related genes from 378 lung cancer patients and 450 healthy people. They found that a variant called "rs4648127" in the NFKB1 gene was associated with a 21 percent to 44 percent reduced risk of lung cancer.
A protein produced in part from the NFKB1 gene is known to play an important role in inflammation and immunity by regulating gene expression, cell death and cell proliferation.
The study was published online Oct. 8 in the journal Cancer.
"Our study provides further evidence that inflammation may be associated with lung cancer risk," study co-author Meredith Shiels, of the U.S. National Cancer Institute, said in a journal news release.
Further research is needed to learn more about the link between the NFKB1 gene and lung cancer, she added.
While the study found an association between a gene variant and lung cancer risk, it did not prove a cause-and-effect relationship.
More information
The U.S. Centers for Disease Control and Prevention has more about lung cancer risk factors.
(SOURCE: Cancer, news release, Oct. 8, 2012)
Copyright © 2012 HealthDay.
All rights reserved.HealthDayNews articles are derived from various sources and do not reflect federal policy. healthfinder.gov does not endorse opinions, products, or services that may appear in news stories. For more information on health topics in the news, visit Health News on healthfinder.gov.
View the original article here
